ArticleChemistry & biodiversity2026
Extracts of Baccharis conferta Kunth Reduce Carrageenan-Induced Paw Edema in Mice and Inhibit NF-κB in LPS-Stimulated RAW-Blue Macrophages.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study evaluated the anti-inflammatory effects and chemical profiles of hexane (BcH), dichloromethane (BcD), and methanol (BcM) extracts from Baccharis conferta using LPS-stimulated RAW-Blue macrophages and a carrageenan-induced paw edema model in mice. GC/MS analysis of BcH identified heptacosane (30.89%), 3β-myristoylolean-12-en-16β-ol (7.88%), and spathulenol (5.8%) as major components. UPLC-MS analysis showed distinct profiles for BcD and BcM extracts; BcD was characterized by flavonoids such as cirsimaritin, acacetin, and pectolinaringenin, while BcM contained chlorogenic acids (5-O-caffeoylquinic acid, 1-O-caffeoylquinic acid, 3,4-di-O-caffeoylquinic acid, and 4,5-di-O-caffeoylquinic acid), and flavonoids (vicenin-2 and rutin). In vivo, oral administration of all extracts (100 mg/kg) reduced paw edema, with BcD and BcM significantly decreasing paw swelling from 3 h onward, with effects comparable to those of the reference drug meloxicam (P < 0.05), while BcH showed lower activity. In vitro, the effects of the extracts were assessed using SEAP reporter activity as an indicator of NF-κB/AP-1 signaling. BcD and BcM significantly reduced SEAP activity in a concentration-dependent manner, whereas BcH showed a lower inhibitory effect. Overall, extracts of B. conferta exert anti-inflammatory activity by modulating NF-κB/AP-1 signaling. These findings support the potential of B. conferta as a promising candidate for treating inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.